Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Diana Zatreanu(Institute of Cancer Research), Christopher J. Lord(Institute of Cancer Research)
Cited by 347
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
|Cancer Discovery|2017|422
Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma
|Science Translational Medicine|2011|401